News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
6,494 Results
Type
Article (773)
Press Release (5721)
Section
Business (1805)
Career Advice (5)
Deals (405)
Drug Delivery (4)
Drug Development (703)
Employer Resources (1)
FDA (264)
Job Trends (164)
News (3659)
Policy (822)
Tag
Academia (10)
Alliances (365)
Alzheimer's disease (2)
Approvals (266)
Artificial intelligence (4)
Autoimmune disease (2)
Bankruptcy (5)
Best Places to Work (71)
Biosimilars (54)
Cancer (1)
Career advice (4)
Cell therapy (1)
Clinical research (627)
Collaboration (11)
Complete response letters (2)
COVID-19 (18)
C-suite (10)
Data (24)
Denatured (3)
Diabetes (1)
Diagnostics (7)
Digital health (1)
Diversity, equity & inclusion (1)
Drug pricing (10)
Drug shortages (1)
Duchenne muscular dystrophy (1)
Earnings (694)
Editorial (1)
Employer resources (1)
Events (517)
Executive appointments (10)
FDA (286)
Funding (5)
Gene therapy (1)
GLP-1 (11)
Government (98)
Guidances (4)
Healthcare (68)
Immunology and inflammation (6)
Indications (2)
Infectious disease (18)
Inflammatory bowel disease (14)
Inflation Reduction Act (1)
IPO (83)
IRA (3)
Job creations (87)
Job search strategy (4)
JPM (2)
Labor market (5)
Layoffs (23)
Legal (456)
Manufacturing (2)
MASH (2)
Medical device (21)
Medtech (21)
Mergers & acquisitions (324)
Metabolic disorders (7)
mRNA (2)
Multiple sclerosis (4)
Neurodegenerative disease (1)
Neuropsychiatric disorders (1)
Neuroscience (22)
NextGen: Class of 2026 (42)
Non-profit (8)
Now hiring (1)
Obesity (4)
Opinion (8)
Patents (4)
People (713)
Pharmacy benefit managers (2)
Phase 1 (78)
Phase 2 (190)
Phase 3 (350)
Pipeline (49)
Policy (6)
Postmarket research (69)
Preclinical (30)
Prostate cancer (1)
Radiopharmaceuticals (1)
Rare diseases (3)
Real estate (31)
Regulatory (318)
Reports (1)
Research institute (9)
RNA editing (2)
Schizophrenia (11)
Series A (1)
Special edition (1)
Startups (28)
Supply chain (1)
Vaccines (2)
Weight loss (3)
Women's health (1)
Date
Today (2)
Last 7 days (2)
Last 30 days (7)
Last 365 days (151)
2026 (39)
2025 (160)
2024 (265)
2023 (240)
2022 (815)
2021 (584)
2020 (462)
2019 (329)
2018 (328)
2017 (378)
2016 (330)
2015 (516)
2014 (310)
2013 (280)
2012 (259)
2011 (251)
2010 (217)
Location
Africa (13)
Arizona (1)
Asia (1788)
Australia (58)
California (35)
Canada (8)
China (2)
Connecticut (2)
Delaware (1)
Europe (1064)
Florida (10)
Illinois (6)
Indiana (1)
Japan (2)
Maryland (1)
Massachusetts (22)
Minnesota (1)
Missouri (1)
New Jersey (47)
New York (7)
North Carolina (2)
Northern California (20)
Ohio (1)
Pennsylvania (4)
Rhode Island (2)
South America (12)
Southern California (12)
Texas (2)
United States (128)
Utah (2)
Washington D.C. (4)
Washington State (2)
Wisconsin (1)
6,494 Results for "teva".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026
·
8 min read
Press Releases
Teva Releases Q1 2026 Aide Memoire
March 20, 2026
·
2 min read
Press Releases
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
April 29, 2026
·
50 min read
Press Releases
Teva to Present at the Upcoming Investor Conferences in March
February 25, 2026
·
3 min read
Press Releases
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
April 15, 2026
·
9 min read
Obesity
Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda
In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.
August 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
February 17, 2026
·
12 min read
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
The funding comes weeks after TL1A blocker duvakitug maintained clinical remission rates above 50% in patients with ulcerative colitis and Crohn’s disease in a Phase 2b trial.
March 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 22, 2026
·
9 min read
Press Releases
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
March 4, 2026
·
6 min read
1 of 650
Next
